Tobira Therapeutics Inc. (TBRA) Lowered to Hold at Cantor Fitzgerald
Tobira Therapeutics Inc. (NASDAQ:TBRA) was downgraded by investment analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating in a report issued on Wednesday.
Several other equities analysts have also commented on TBRA. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Zacks Investment Research upgraded shares of Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research report on Wednesday, July 13th. Finally, Cowen and Company reiterated a “buy” rating and issued a $11.00 target price on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $16.75.
Tobira Therapeutics (NASDAQ:TBRA) opened at 38.91 on Wednesday. Tobira Therapeutics has a 12 month low of $3.76 and a 12 month high of $41.39. The firm’s 50-day moving average is $5.61 and its 200-day moving average is $8.26. The firm’s market cap is $732.33 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/tobira-therapeutics-inc-tbra-lowered-to-hold-at-cantor-fitzgerald.html
Tobira Therapeutics (NASDAQ:TBRA) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.08. The firm had revenue of $1.06 million for the quarter. Equities analysts expect that Tobira Therapeutics will post ($2.65) earnings per share for the current year.
In other Tobira Therapeutics news, major shareholder A/S Novo sold 92,119 shares of the company’s stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $12.20, for a total value of $1,123,851.80. Following the completion of the sale, the insider now directly owns 2,016,691 shares of the company’s stock, valued at approximately $24,603,630.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.20% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of TBRA. Franklin Resources Inc. acquired a new stake in shares of Tobira Therapeutics during the first quarter worth $4,797,000. State Street Corp increased its stake in shares of Tobira Therapeutics by 184.3% in the first quarter. State Street Corp now owns 42,875 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 27,794 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Tobira Therapeutics by 2.5% in the first quarter. Geode Capital Management LLC now owns 32,223 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 799 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Tobira Therapeutics during the second quarter worth $263,000. Finally, California State Teachers Retirement System increased its stake in shares of Tobira Therapeutics by 230.2% in the second quarter. California State Teachers Retirement System now owns 18,578 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 12,951 shares during the last quarter. 62.02% of the stock is owned by institutional investors.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.